| Code | CSB-RA614981MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to erenumab, targeting the calcitonin receptor-like receptor (CALCRL). CALCRL, also known as CLR, functions as a critical component of the calcitonin gene-related peptide (CGRP) receptor complex. When paired with receptor activity-modifying protein 1 (RAMP1), CALCRL forms the functional CGRP receptor, which mediates vasodilation and pain transmission pathways. This receptor complex plays a pivotal role in migraine pathophysiology, cardiovascular regulation, and nociceptive signaling, making it a significant target for neurological and pain research.
Erenumab is the world's first approved preventive treatment drug targeting the CGRP receptor. It achieves this by blocking the CGRP receptor, thereby inhibiting the neurogenic inflammation and pain signal transmission associated with migraine attacks, and reducing the number of migraine days per month. This biosimilar provides researchers with a valuable tool for investigating CGRP receptor biology, studying migraine mechanisms, and exploring pain modulation pathways. It enables investigation of receptor-ligand interactions, downstream signaling cascades, and therapeutic intervention strategies in headache disorders and related neurological conditions.
There are currently no reviews for this product.